Mosanna is a Swiss Biotech company based in Basel with a commitment to improving patient outcomes and quality of life in high unmet need diseases, applying a precision medicine approach. We carefully select innovative medicines for further development using the best contract research organisations in the specific specialised field. Our first goal is to bring an effective and well tolerated medicinal nasal spray to Metabolic Obstructive Sleep Apnea patients.

Press releases

11. April 2023

Mosanna Therapeutics Announces a Seed Extension Financing Round to Complete Preparations to Enter the Clinic with MOS-118 in Metabolic Obstructive Sleep Apnea

Company pursuing a highly differentiated small molecule MOS-118 in Metabolic Obstructive Sleep Apnea. New investors, Supermoon Capital and HTGF, join founding investor Forty51 Ventures to complete the Seed syndicate. Company will use the funds to file an IND in preparation for a proof of mechanism and proof of concept in the clinic. Basel, Switzerland, April 11, 2023 - Mosanna Therapeutics AG, a Swiss Biotech company today announced that Supermoon Capital, a US based venture c

Info & Contact


Mosanna Therapeutics AG
Grellingerstrasse 91
4052 Basel

In portfolio

HTGF Manager

Dr. Laura Pedroza, Investment Manager